Diacylglycerol kinase alpha (DGKA) as a novel epigenetic marker for developing fibrosis after radiotherapy
DKFZ Deutsches Krebsforschungszentrum
Radiation-induced fibrosis is a common severe side effect of radiation therapy. No reliable marker currently exists for the prediction of radiation-induced fibrosis. Therefore, the present invention reveals a method for estimating the risk of developing radiation-induced fibrosis for use in therapy planning.
The risk of developing radiation-induced fibrosis can be estimated by determining the methylation status of several GpC sites in an intragenic region of the DGKA gene. We were able to determine a very high overall prediction accuracy (area under the ROC curve) of 0.77.
- A frequent side effect of radiotherapy is that cancer patients develop fibrosis
- Fibrosis can be estimated by determination of the methylation status
- Fibrosis risk after radiation therapy is predicted by analyzing intragenic methylation sites of the DKGA gene
The results were established using an in vitro method, and the statistical analysis is based on a cohort of 40 patients.
Applications and Commercial Opportunity
DKFZ is looking for a commercial partner to further validate and commercialize the test.
The investigators are: Weigel C., Schmezer P., Chang-Claude J., Wenz F., Herskind C., Veldwijk M., Sperk E., and Popanda O.
All inventors are employed either by DKFZ or University of Heidelberg.
A European Patent application has been filed.
EP 14002963, priority date: 27.08.2014
No other public information is currently available, but further information (speaking with the inventors) is available under a signed Confidential Disclosure Agreement (CDA).